The growing tension between the innovator and generic drug industries over access to branded products for bioequivalence testing is moving beyond the framework of restricted distribution programs under Risk Evaluation and Mitigation Strategies.
Legal disputes are on the rise in which generic drug manufacturers assert the brand company has used a voluntary restricted...